Biomarkers of metastatic potential in cultured adenocarcinoma clones

Clinical and Experimental Metastasis

Volumn 28, Issue 2, 2011, Pages 101-111

  Dabbous, Mustafa Kh ^a   Jefferson, Margaret M ^a   Lena, Haney ^a   Thomas, Edwin L ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adenocarcinoma; Biomarkers; Metastasis; Proteome

Indexed keywords

GALECTIN 1; PEROXIREDOXIN 2; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN 14 3 3; TUMOR MARKER; PEROXIREDOXIN;

ANIMAL CELL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CELL CLONE; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; RAT; ADENOCARCINOMA; ANIMAL; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANIMALS; CLONE CELLS; FEMALE; GALECTIN 1; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM METASTASIS; PEROXIREDOXINS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RATS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79953326806     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9362-8     Document Type: Article

References (52)

1. Brünner N, Holten-Andersen M, Sweep F et al (2008) New tumor biomarkers: practical considerations prior to clinical application. In: Daoud SS (ed) Cancer proteomics from bench to bedside. Human Press, Totowa, pp 189-207
2. Verma M, Srivastava S (2003) New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 163:72-84 discussion 264-266
3. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312 (Pubitemid 350232263)
4. Couzin J (2009) Biomarkers. Metabolite in urine may point to high-risk prostate cancer. Science 323:865
5. Li H, He Y, Ding G et al (2010) DbDEPC: a database of differentially expressed proteins in human cancers. Nucl Acids Res 38:D658-D664
6. Conrads TP, Hood BL, Petricoin EF 3rd et al (2005) Cancer proteomics: many technologies, one goal. Expert Rev Proteomics 2:693-703 (Pubitemid 41492391)
7. Reymond MA, Schlegel W (2007) Proteomics in cancer. Adv Clin Chem 44:103-142
8. Rajcevic U, Niclou SP, Jimenez CR (2009) Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci 14:3292-3303
9. Neri A, Welch D, Kawaguchi T et al (1982) Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst 68:507-517 (Pubitemid 12156692)
10. Ramshaw IA, Badenoch-Jones P (1985) Studies on rat mammary adenocarcinomas: a model for metastasis. Cancer Metastasis Rev 4:195-208
11. Atnip KD, Carter LM, Nicolson GL et al (1987) Chemotactic response of rat mammary adenocarcinoma cell clones to tumor-derived cytokines. Biochem Biophys Res Commun 146: 996-1002
12. Dabbous MK, Haney L, Nicolson GL et al (1991) Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF. Br J Cancer 63:873-878
13. Pencil SD, Toh Y, Nicolson GL (1993) Candidate metastasisassociated genes of the rat 13762NF mammary adenocarcinoma. Breast Cancer Res Treat 25:165-174 (Pubitemid 23170615)
14. Toh Y, Pencil SD, Nicolson GL (1995) Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene 159:97-104
15. Pencil SD, Toth M (1998) Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clin Exp Metastasis 16:113-121 (Pubitemid 28252918)
16. Levea CM, Mcgary CT, Symons JR et al (2000) PTP LAR expression compared to prognostic indices in metastatic and nonmetastatic breast cancer. Breast Cancer Res Treat 64:221-228 (Pubitemid 32010340)
17. Bouzahzah B, Albanese C, Ahmed F et al (2001) Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med 7:816-830 (Pubitemid 34175305)
18. Wang W, Wyckoff JB, Frohlich VC et al (2002) Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 62:6278-6288 (Pubitemid 35244482)
19. van Nimwegen MJ, Verkoeijen S, van Buren L et al (2005) Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res 65:4698-4706 (Pubitemid 40740806)
20. Xue C, Wyckoff J, Liang F et al (2006) Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 66:192-197 (Pubitemid 43166025)
21. Sidani M, Wessels D, Mouneimne G et al (2007) Cofilin determines the migration behavior and turning frequency of metastatic cancer cells. J Cell Biol 179:777-791 (Pubitemid 350146261)
22. Wang W, Wyckoff JB, Goswami S et al (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res 67:3505-3511 (Pubitemid 46762128)
23. Hernandez L, Smirnova T, Kedrin D et al (2009) The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin {beta}1 and CXCL12. Cancer Res 69:3221-3227
24. Marxfeld H, Staedtler F, Harleman JH (2006) Characterisation of two rat mammary tumour models for breast cancer research by gene expression profiling. Exp Toxicol Pathol 58:133-143 (Pubitemid 44635150)
25. Wilkins MR, Pasquali C, Appel RD et al (1996) From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Nat Biotechnol 14:61-65
26. Srinivas PR, Verma M, Zhao Y et al (2002) Proteomics for cancer biomarker discovery. Clin Chem 48:1160-1169 (Pubitemid 34809820)
27. Alaiya A, Al-Mohanna M, Linder S (2005) Clinical cancer proteomics: promises and pitfalls. J Proteome Res 4:1213-1222 (Pubitemid 41213336)
28. Iwadate Y (2008) Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis. Curr Med Chem 15:2393-2400
29. Zhang K, Wrzesinski K, Stephen JF et al (2008) Comparative proteome analysis of three mouse lung adenocarcinoma CMT cell lines with different metastatic potential by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 8:4932-4945
30. Sitek B, Sipos B, Alkatout I et al (2009) Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J Proteome Res 8: 1647-1656
31. Sommers CL, Heckford SE, Skerker JM et al (1992) Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 52:5190-5197
32. Okuwaki M (2008) The structure and functions of NPM1/Nucleophosmin/ B23, a multifunctional nucleolar acidic protein. J Biochem 143:441-448 (Pubitemid 351451762)
33. Grisendi S, Mecucci C, Falini B et al (2006) Nucleophosmin and cancer. Nat Rev Cancer 6:493-505 (Pubitemid 43980539)
34. Mhawech P (2005) 14-3-3 proteins-an update. Cell Res 15: 228-236
35. Keller ET, Fu Z, Yeung K et al (2005) The biology of a prostate cancer metastasis suppressor protein: raf kinase inhibitor protein. J Cell Biochem 1:273-278 (Pubitemid 41420306)
36. Klysik J, Theroux SJ, Sedivy JM et al (2008) Signaling crossroads: the function of raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal 20:1-9 (Pubitemid 350138364)
37. Granovsky AE, Rosner MR (2008) Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res 18:452-457 (Pubitemid 351498852)
38. Fu Z, Kitagawa Y, Shen R et al (2006) Metastasis suppressor gene raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66:248-256 (Pubitemid 43191224)
39. Fu Z, Smith PC, Zhang L et al (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:878-889 (Pubitemid 36833879)
40. Neumann CA, Fang Q (2007) Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7:375-380 (Pubitemid 47289263)
41. Petrak J, Ivanek R, Toman O et al (2008) Deja vu in proteomics. a hit parade of repeatedly identified differentially expressed proteins. Proteomics 8:1744-1749 (Pubitemid 351678270)
42. Gromov P, Gromova I, Bunkenborg J et al (2010) Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol 4:65-89
43. Camby I, Le Mercier M, Lefranc F et al (2006) Galectin-1: a small protein with major functions. Glycobiology 16:137R-157R (Pubitemid 44530693)
44. Salatino M, Croci DO, Bianco GA et al (2008) Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin Biol Ther 28:45-57 (Pubitemid 351233722)
45. Wu MH, Hong TM, Cheng HW et al (2009) Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res 7:311-318
46. Thijssen VL, Postel R, Brandwijk RJ et al (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975-15980 (Pubitemid 44657577)
47. Daroqui CM, Ilarregui JM, Rubinstein N et al (2007) Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol Immunother 56:491-499 (Pubitemid 46204535)
48. Rabinovich GA, Liu FT, Hirashima M et al (2007) An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol 66:143-158 (Pubitemid 47063211)
49. Jung EJ, Moon HG, Cho BI et al (2007) Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120:2331-2338
50. Saussez S, Lorfevre F, Lequeux T et al (2008) The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol 44:86-93 (Pubitemid 350251284)
51. Saussez S, Glinoer D, Chantrain G et al (2008) Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18:705-712 (Pubitemid 352009927)
52. Chiang WF, Liu SY, Fang LY et al (2008) Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol 44:325-334